Place Raymond Blyckaerts, 13
B-1050 Brussels, Belgium

Opening hours:
Mon to Thu: 10h - 12h30 and 13h30 - 17h
Fri: 10h - 12h30 and 13h30 - 16h


+3226269640
Google maps


Find us on
Google Maps
To subscribe to our newsletter, please click here. If you would like to become an EATG member, please fill in the form here. You can also subscribe to our RSS feed by clicking here.
You can also follow us on one of these media :
TAGS

26/02/2015
HIV maturation inhibitor BMS-955176 looks promising in early study

A second-generation HIV maturation inhibitor, BMS-955176, demonstrated good safety and high potency, including activity against viral strains that were not susceptible to an earlier drug in this class, researchers reported yesterday at the Conference on Retroviruses and Opportunistic Infections (CROI 2015) , taking place this week in Seattle, USA. Combination...

Read more...

Source Source: Aidsmap





26/02/2015
Starting HIV treatment at CD4 count above 500 reduces the risk of serious illness and death by 44%, African Temprano trial shows

Starting HIV treatment at a CD4 cell count above 500 reduced the risk of serious illness including tuberculosis (TB), and death, by 44% when compared to starting treatment according to World Health Organization (WHO) guidelines, results from the seven-year Temprano study show. The findings were presented on Wednesday at the Conference on Retroviruses and Opportunistic Infections (CROI...

Read more...

Source Source: Aidsmap





26/02/2015
XDR-TB in South Africa is largely spread person-to-person, not by failure of drug treatment

The vast majority of people with extensively drug-resistant tuberculosis (XDR-TB) diagnosed in the world’s most extensive outbreak have acquired their infection from another person, not as the result of the failure of treatment for multidrug-resistant strains of tuberculosis (MDR-TB), N Sarita Shah told the Conference on Retroviruses and Opportunistic Infections (CROI...

Read more...

Source Source: Aidsmap





26/02/2015
ABIVAX recruits first patient in a pivotal Phase IIb/III clinical trial with ABX203, a novel immunotherapy against chronic hepatitis B

Paris, February 26, 2015 – ABIVAX, a clinical stage biotech company developing and commercialising anti-viral compounds and human vaccines, today announced that it has dosed in New Zealand the first patient in a Phase IIb/III clinical trial of ABX203 which is taking place in several countries of the Asia-Pacific region. The study is designed to assess whether ABX203 can deliver a...

Read more...

Source Source: ABIVAX





26/02/2015
Zero Discrimination Day to be celebrated around the world

GENEVA, 26 February 2015—Discrimination continues to affect the lives of millions of people around the world. On 1 March, Zero Discrimination Day , people from all corners of the world will unite under the theme of Open Up, Reach Out in order to celebrate diversity and reject discrimination in all its forms. The support garnered for Zero Discrimination Day has created a...

Read more...

Source Source: UNAIDS